{"id":"doravirine-tenofovir-lamivudine-open-label","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Insomnia"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Doravirine works by binding to the HIV-1 reverse transcriptase enzyme, preventing the replication of the virus. Tenofovir and Lamivudine work by inhibiting the HIV-1 reverse transcriptase enzyme, thereby preventing the replication of the virus. This combination of drugs is used to treat HIV-1 infection.","oneSentence":"Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI), while Tenofovir and Lamivudine are HIV-1 nucleotide reverse transcriptase inhibitors (NtRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs), respectively.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:34:24.085Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection in adults with no antiretroviral treatment history or with viral suppression on a stable antiretroviral regimen for at least 6 months"}]},"trialDetails":[{"nctId":"NCT06203132","phase":"PHASE3","title":"DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-01-27","conditions":"HIV-1-infection","enrollment":610},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT04233372","phase":"PHASE4","title":"Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2020-08-27","conditions":"Hiv","enrollment":399},{"nctId":"NCT06034938","phase":"PHASE2","title":"DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)","status":"RECRUITING","sponsor":"University Hospital, Caen","startDate":"2024-02-08","conditions":"Hiv","enrollment":32},{"nctId":"NCT02652260","phase":"PHASE2","title":"Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-03-04","conditions":"HIV-1, Central Nervous System","enrollment":86},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT02397096","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-09","conditions":"HIV-1 Infection","enrollment":673},{"nctId":"NCT02275780","phase":"PHASE3","title":"Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-12-01","conditions":"HIV-1","enrollment":769},{"nctId":"NCT03272347","phase":"PHASE2","title":"Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-11-27","conditions":"HIV-1 Infection","enrollment":123},{"nctId":"NCT02629822","phase":"PHASE2","title":"Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-14","conditions":"HIV-1 Infection","enrollment":10},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK-1439A"],"phase":"phase_2","status":"active","brandName":"Doravirine, Tenofovir, Lamivudine - Open-Label","genericName":"Doravirine, Tenofovir, Lamivudine - Open-Label","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI), while Tenofovir and Lamivudine are HIV-1 nucleotide reverse transcriptase inhibitors (NtRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs), respectively. Used for Treatment of HIV-1 infection in adults with no antiretroviral treatment history or with viral suppression on a stable antiretroviral regimen for at least 6 months.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}